Literature DB >> 30892978

Evaluation of platelet function in essential thrombocythemia under different analytical conditions.

Federico Lussana1, Eti Alessandra Femia1, Mariateresa Pugliano1, Gianmarco Podda1, Cristina Razzari1, Norma Maugeri2, Anna Lecchi3, Sabrina Caberlon1, Giancarla Gerli1, Marco Cattaneo1.   

Abstract

Background. Studies of platelet aggregation (PA) in essential thrombocythemia (ET) reported contrasting results, likely due to differences in analytical conditions.Objective. We investigated platelet aggregation using different techniques and analytical conditions.Patients and Methods. PA was studied by light-transmission aggregometry (LTA) in platelet-rich plasma (PRP) and impedance aggregometry in PRP and whole blood (WB). ADP, collagen, thrombin receptor activating peptide (TRAP-14) and adrenaline were used as agonists. Since ET patients (n = 41) were on treatment with aspirin (100 mg/d), healthy controls (n = 29) were given aspirin (100 mg/d) for 5 days before testing: therefore, thromboxane A2-independent PA was tested in all subjects. Blood samples were collected in citrate (C) [low Ca2+] or lepirudin (L) [physiological Ca2+]; platelet count was adjusted to 250 x 109/L in a set of C-PRP (adjusted C-PRP) and left unmodified in the other samples.Results. Results of PA in 17 ET patients who were poor responders to aspirin (high serum thromboxane B2 levels) were not included in the analysis. With LTA, PA in ET was lower than in controls in adjusted C-PRP and normal in native C-PRP and L-PRP. With impedance aggregometry, PA in L-PRP and L-WB tended to be higher in ET than in controls. Platelet serotonin and ADP contents were reduced in ET. The percentages of circulating platelets expressing P-selectin and platelet-leukocyte hetero-aggregates were higher in ET.Conclusions. Analytical conditions dramatically affect in vitro PA of ET patients, which appears defective under the least physiological conditions and normal/supranormal under conditions that are closer to the physiological.

Entities:  

Keywords:  Disorders of platelets; myeloproliferative disorders; platelet aggregation; platelet function test; platelet rich plasma

Year:  2019        PMID: 30892978     DOI: 10.1080/09537104.2019.1584668

Source DB:  PubMed          Journal:  Platelets        ISSN: 0953-7104            Impact factor:   3.862


  3 in total

Review 1.  Platelets as Mediators of Thromboinflammation in Chronic Myeloproliferative Neoplasms.

Authors:  Cecilia P Marin Oyarzún; Paula G Heller
Journal:  Front Immunol       Date:  2019-06-14       Impact factor: 7.561

2.  Platelet Reactivity and Response to Aspirin and Clopidogrel in Patients with Platelet Count Disorders.

Authors:  Wiktor Kuliczkowski; Ewa Żurawska-Płaksej; Maria Podolak-Dawidziak; Magdalena Cielecka-Prynda; Bożena Karolko; Jakub Dębski; Konrad Kaaz; Marcin Protasiewicz; Iwona Prajs; Andrzej Mysiak; Tomasz Wróbel; Lidia Usnarska-Zubkiewicz
Journal:  Cardiol Res Pract       Date:  2021-04-17       Impact factor: 1.866

3.  "Unconventional CD147-dependent platelet activation elicited by SARS-CoV-2 in COVID-19": Reply.

Authors:  Norma Maugeri; Angelo A Manfredi
Journal:  J Thromb Haemost       Date:  2022-09       Impact factor: 16.036

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.